Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 1

From BugSigDB


Reviewed Marked as Reviewed by Svetlana up on 2025-4-14

Curated date: 2025/03/31

Curator: Eniola

Revision editor(s): Eniola, Shulamite, KateRasheed

Subjects

Location of subjects
Spain
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Viral disease infection, viral,infections, Viruses,viral disease,viral disorder,viral infection,viral infectious disease,virus infection,Viruses caused disease or disorder,Viruses disease or disorder,Viruses infection,Viruses infectious disease,Viral disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Total bacteria isolated before treatments + IgG isotype control pAb or the specific pAb + IgG isotype control pAb (T+C+N))
Group 1 name Corresponds to the case (exposed) group for case-control studies
anti-NoV GII.4 Sydney 2012 pAb (NoV)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Bacteria captured by anti-NoV GII.4 Sydney 2012 pAb
Group 0 sample size Number of subjects in the control (unexposed) group
3
Group 1 sample size Number of subjects in the case (exposed) group
1

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3


Signature 1

Reviewed Marked as Reviewed by Svetlana up on 2025-4-14

Curated date: 2025/03/31

Curator: Shulamite

Revision editor(s): Shulamite, Eniola

Source: Fig 1a

Description: LDA of bacterial genera quantified from clinical samples with NoV. The LDA score of 15 taxa with significant differences (p<0.05 in Kruskal-Wallis test, adjusted by FDR) in a LEfse analysis is presented.

Abundance in Group 1: increased abundance in anti-NoV GII.4 Sydney 2012 pAb (NoV)

NCBI Quality ControlLinks
Agrobacterium
Allobaculum
Brevibacterium
Pandoraea
Stenotrophomonas
Pseudomonas
Methylobacterium
Staphylococcus
Rhodococcus
Bulleidia
Chryseobacterium
Sphingomonas
Ochrobactrum
Rothia

Revision editor(s): Shulamite, Eniola

Signature 2

Reviewed Marked as Reviewed by Svetlana up on 2025-4-14

Curated date: 2025/03/31

Curator: Shulamite

Revision editor(s): Shulamite, Eniola

Source: Fig 1a

Description: LDA of bacterial genera quantified from clinical samples with NoV. The LDA score of 15 taxa with significant differences (p<0.05 in Kruskal-Wallis test, adjusted by FDR) in a LEfse analysis is presented.

Abundance in Group 1: decreased abundance in anti-NoV GII.4 Sydney 2012 pAb (NoV)

NCBI Quality ControlLinks
Candidatus Tremblayella

Revision editor(s): Shulamite, Eniola